An update on antibody-based immunotherapies for Clostridium difficile infection

From National Research Council Canada

Download
  1. (PDF, 1 MB)
DOIResolve DOI: https://doi.org/10.2147/CEG.S84017
AuthorSearch for: 1; Search for: 1
Name affiliation
  1. National Research Council of Canada. Human Health Therapeutics
FormatText, Article
Journal titleClinical and Experimental Gastroenterology
ISSN1178-7023
1178-7023
Volume9
Pages209–224
Subjectantibody; Clostridium difficile; immunotherapy; toxin
Abstract
Clostridium difficile continues to be one of the most prevalent hospital-acquired bacterial infections in the developed world, despite the recent introduction of a novel and effective antibiotic agent (fidaxomicin). Alternative approaches under investigation to combat the anaerobic Gram-positive bacteria include fecal transplantation therapy, vaccines, and antibody-based immunotherapies. In this review, we catalog the recent advances in antibody-based approaches under development and in the clinic for the treatment of C. difficile infection. By and large, inhibitory antibodies that recognize the primary C. difficile virulence factors, toxin A and toxin B, are the most popular passive immunotherapies under investigation. We provide a detailed summary of the toxin epitopes recognized by various antitoxin antibodies and discuss general trends on toxin inhibition efficacy. In addition, antibodies to other C. difficile targets, such as surface-layer proteins, binary toxin, motility factors, and adherence and colonization factors, are introduced in this review.
Publication date
PublisherDove Medical Press
LanguageEnglish
Peer reviewedYes
NRC numberNRC-HHT-53318
NPARC number23000647
Export citationExport as RIS
Report a correctionReport a correction
Record identifiercb331245-37fb-4216-864c-5b5e832a8377
Record created2016-08-17
Record modified2020-06-02
Report a problem on this page
Date modified: